Amgen/$AMGN
13:30
21:10
04:45
12:25
20:00
1D1W1MYTD1Y5YMAX
About Amgen
Amgen is a leader in biotechnology-based human therapeutics. Flagship drugs include red blood cell boosters Epogen and Aranesp, immune system boosters Neupogen and Neulasta, and Enbrel and Otezla for inflammatory diseases. Amgen introduced its first cancer therapeutic, Vectibix, in 2006 and markets bone-strengthening drugs Prolia/Xgeva (approved 2010) and Evenity (2019). The acquisition of Onyx Pharmaceuticals bolstered the firm's therapeutic oncology portfolio with Kyprolis. Recent launches include Repatha (cholesterol-lowering), Aimovig (migraine), Lumakras (lung cancer), and Tezspire (asthma). The 2023 Horizon acquisition brought several rare-disease drugs, including thyroid eye disease drug Tepezza. Amgen also has a growing biosimilar portfolio.
Ticker
$AMGN
Sector
Primary listing
Industry
Biotechnology
Headquarters
Employees
28,000
ISIN
US0311621009
Website
Amgen Metrics
BasicAdvanced
$150B
25.51
$10.94
0.50
$9.26
3.41%
Price and volume
Market cap
$150B
Beta
0.5
52-week high
$346.85
52-week low
$253.30
Average daily volume
2.9M
Dividend rate
$9.26
Financial strength
Current ratio
1.17
Quick ratio
0.736
Long term debt to equity
870.195
Total debt to equity
924.456
Dividend payout ratio (TTM)
82.64%
Interest coverage (TTM)
2.96%
Profitability
EBITDA (TTM)
15,726
Gross margin (TTM)
69.07%
Net profit margin (TTM)
17.39%
Operating margin (TTM)
30.08%
Effective tax rate (TTM)
10.78%
Revenue per employee (TTM)
$1,220,000
Management effectiveness
Return on assets (TTM)
7.04%
Return on equity (TTM)
105.67%
Valuation
Price to earnings (TTM)
25.506
Price to revenue (TTM)
4.396
Price to book
24.18
Price to tangible book (TTM)
-3.93
Price to free cash flow (TTM)
13.745
Free cash flow yield (TTM)
7.28%
Free cash flow per share (TTM)
2,030.70%
Dividend yield (TTM)
3.32%
Forward dividend yield
3.41%
Growth
Revenue change (TTM)
15.56%
Earnings per share change (TTM)
56.16%
3-year revenue growth (CAGR)
9.05%
10-year revenue growth (CAGR)
5.19%
3-year earnings per share growth (CAGR)
2.64%
10-year earnings per share growth (CAGR)
3.98%
3-year dividend per share growth (CAGR)
8.14%
10-year dividend per share growth (CAGR)
13.30%
What the Analysts think about Amgen
Analyst ratings (Buy, Hold, Sell) for Amgen stock.
Bulls say / Bears say
Amgen's $27.8 billion acquisition of Horizon Therapeutics, approved by the FTC, is expected to enhance its portfolio with high-growth drugs, potentially boosting revenue. (reuters.com)
Analysts maintain a 'Moderate Buy' consensus on Amgen, with an average price target of $317.69, indicating potential upside from current levels. (markets.businessinsider.com)
Amgen's investment of approximately $200 million in a new technology center in India demonstrates its commitment to expanding global operations and innovation capacity. (financecharts.com)
Amgen's third-quarter sales rose by 5%, but the full-year sales forecast increase was primarily due to the Horizon acquisition, raising concerns about organic growth. (ca.finance.yahoo.com)
Sales of key products like Enbrel and Tepezza have declined, potentially impacting overall revenue growth. (remsencoop.com)
Amgen's stock price has experienced volatility, with a recent decline of nearly 4%, reflecting investor concerns over future performance. (ca.finance.yahoo.com)
Data summarised monthly by Lightyear AI. Last updated on 23 Jun 2025.
Amgen Financial Performance
Revenues and expenses
Amgen Earnings Performance
Company profitability
Amgen News
AllArticlesVideos
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
Capital at risk
Upcoming events
No upcoming events
FAQs
What’s the current market cap for Amgen stock?
Amgen (AMGN) has a market cap of $150B as of June 27, 2025.
What is the P/E ratio for Amgen stock?
The price to earnings (P/E) ratio for Amgen (AMGN) stock is 25.51 as of June 27, 2025.
Does Amgen stock pay dividends?
Yes, the Amgen (AMGN) stock pays dividends to shareholders. As of June 27, 2025, the dividend rate is $9.26 and the yield is 3.41%. Amgen has a payout ratio of 82.64% on a trailing twelve-month basis.
When is the next Amgen dividend payment date?
The next Amgen (AMGN) dividend payment date is unconfirmed.
What is the beta indicator for Amgen?
Amgen (AMGN) has a beta rating of 0.5. This means that it is less volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 0.5 would mean it moves half as much as the market.